Martingale Asset Management
PCRX icon

Martingale Asset Management’s Pacira BioSciences PCRX Stock Holding History

Martingale Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.34M Buy
133,327
+21,302
+19% +$540K 0.08% 252
2026
Q2 		$2.84M Buy
112,025
+3,202
+3% +$75.7K 0.07% 315
2026
Q1 		$2.46M Buy
108,823
+40,621
+60% +$903K 0.06% 296
2025
Q4 		$1.77M Sell
68,202
-10,495
-13% -$250K 0.04% 350
2025
Q3 		$2.03M Buy
78,697
+14,204
+22% +$349K 0.05% 312
2025
Q2 		$1.54M Buy
64,493
+32,009
+99% +$807K 0.04% 364
2025
Q1 		$807K Buy
+32,484
New +$778K 0.02% 508
2023
Q3 		– Sell
-6,507
Closed -$261K – 830
2023
Q2 		$261K Hold
6,507
– – 0.01% 722
2023
Q1 		$266K Sell
6,507
-29,510
-82% -$1.17M 0.01% 728
2022
Q4 		$1.39M Buy
36,017
+2,804
+8% +$136K 0.03% 357
2022
Q3 		$1.77M Buy
33,213
+3,501
+12% +$195K 0.04% 281
2022
Q2 		$1.73M Buy
29,712
+291
+1% +$19.1K 0.03% 309
2022
Q1 		$2.25M Buy
29,421
+2,500
+9% +$167K 0.03% 256
2021
Q4 		$1.62M Hold
26,921
– – 0.02% 366
2021
Q3 		$1.51M Buy
26,921
+19,918
+284% +$1.15M 0.02% 392
2021
Q2 		$425K Hold
7,003
– – ﹤0.01% 636
2021
Q1 		$491K Sell
7,003
-1,600
-19% -$114K 0.01% 613
2020
Q4 		$515K Sell
8,603
-9,214
-52% -$540K 0.01% 604
2020
Q3 		$1.07M Sell
17,817
-9,405
-35% -$546K 0.01% 615
2020
Q2 		$1.43M Hold
27,222
– – 0.02% 636
2020
Q1 		$913K Buy
+27,222
New +$1.13M 0.01% 706
2019
Q2 		– Sell
-29,721
Closed -$1.13M – 1051
2019
Q1 		$1.13M Sell
29,721
-498
-2% -$19.4K 0.01% 755
2018
Q4 		$1.3M Buy
+30,219
New +$1.41M 0.02% 641
2015
Q2 		– Sell
-2,300
Closed -$205K – 892
2015
Q1 		$205K Sell
2,300
-102
-4% -$10.3K ﹤0.01% 839
2014
Q4 		$213K Sell
2,402
-5,802
-71% -$549K 0.01% 816
2014
Q3 		$796K Buy
+8,204
New +$798K 0.02% 567

Other funds holding PCRX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

Martingale Asset Management's PCRX Position: Q3 2026 in Review

Martingale Asset Management increased its Pacira BioSciences (PCRX) stake by 19% in Q3 2026, buying an estimated $540K and bringing the position to 133,327 shares worth $3.34M. The position accounts for 0.08% of the portfolio, ranked #252.

Martingale Asset Management first reported a position in PCRX in Q3 2014 and has held it in 26 quarters since. 205 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

  • Martingale Asset Management held 133,327 shares of Pacira BioSciences worth $3.34M as of Q3 2026.
  • Martingale Asset Management bought 21,302 Pacira BioSciences shares in Q3 2026, an estimated $540K.
  • Pacira BioSciences made up 0.08% of Martingale Asset Management's portfolio in Q3 2026, its #252 holding.
  • Martingale Asset Management first reported a position in Pacira BioSciences in Q3 2014 and has held it in 26 quarters since.
  • 205 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on Martingale Asset Management's 13F filing for Q3 2026, filed 12 Nov 2026.